Disease Overview

Lung cancer originates in lung tissue and often shows no early symptoms, yet precision treatment can lead to cure or long-term control. With over 2.2 million new cases annually worldwide and nearly 70% diagnosed at advanced stages, early intervention and treatment are crucial to securing a curative window.

China reports approximately 800,000 new cases yearly—nearly one-third of the global burden—endowing our teams with a depth of experience that ensures precision in delivering individualized care.

Risk Factors

• Smoking (including secondhand smoke) — the leading cause
• Exposure to radon gas, asbestos, and other carcinogens
• Air pollution
• Family history of lung cancer
• Previous radiation therapy to the chest

Symptoms

• Persistent cough that worsens over time
• Chest pain that worsens with deep breathing, coughing, or laughing
• Shortness of breath and wheezing
• Coughing up blood (hemoptysis)
• Unexplained weight loss and fatigue
• Hoarseness
• Loss of appetite

Core Treatment Capabilities at Fosun Health

1. Real-Time Breath-Tracking Radiosurgery (CyberKnife M6)

Lung tumors shift up to 2 cm with each breath. Our CyberKnife M6 system features real-time respiratory tracking and 6D robotic positioning, delivering 0.1mm precision from over 1,600 angles. Early-stage or oligometastatic tumors can be treated in 1–5 non-invasive sessions with curative intent—no anesthesia, no incisions.

2. Interventional-Conversion Arsenal

For patients who cannot undergo surgery, we offer a dual-track interventional platform: thermal and cryoablation (RFA, MWA, cryoablation) for physical tumor destruction, iodine-125 seed implantation for continuous internal radiation, and superselective transarterial infusion delivering 50–100× local drug concentration compared to IV therapy—often converting unresectable tumors to surgical candidates.

3. Lung-Sparing Robotic Surgery

Da Vinci robotic-assisted anatomical segmentectomy and precision lobectomy with 10× magnified 3D vision and tremor-free wristed instruments. Only diseased tissue is removed; every viable unit of healthy lung stays.

4. Targeted Therapy Access Advantage

Asian-prevalent mutations (EGFR, ALK, ROS1, MET exon 14 skipping, RET fusions) have driven East Asian-pioneered strategies. Fourth-generation EGFR-TKIs, novel ALK inhibitors, and bispecific antibodies are in routine use here—often while still in trials elsewhere. Comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US.

Multidisciplinary Approach

Every lung cancer case at Fosun Health is reviewed by a panel comprising thoracic surgery, medical oncology, radiation oncology, interventional radiology, radiology, and pathology specialists. The MDT convenes within 48 hours of complete documentation to deliver a unified, individualized plan.